

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr}VYNDAMAX™

tafamidis capsules

61 mg, Oral

Selective stabilizer of transthyretin

Pfizer Canada ULC
17,300 TransCanada Highway
Kirkland, Quebec H9J 2M5

Date of Initial Authorization:
JUL 09, 2021

Date of Revision:
AUG 16, 2022

Submission Control Number: 256231

RECENT MAJOR LABEL CHANGES

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.1 Dosing Considerations	4
4.2 Recommended Dose and Dosage Adjustment	4
4.4 Administration	5
4.5 Missed Dose	5
5 OVERDOSAGE	5
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	5
7 WARNINGS AND PRECAUTIONS	6
7.1 Special Populations	7
7.1.1 Pregnant Women	7
7.1.2 Breast-feeding.....	7
7.1.3 Pediatrics.....	7
7.1.4 Geriatrics.....	7
8 ADVERSE REACTIONS	7
8.1 Adverse Reaction Overview	7
8.2 Clinical Trial Adverse Reactions	7
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	9
8.5 Post-Market Adverse Reactions.....	9
9 DRUG INTERACTIONS	9
9.2 Drug Interactions Overview	9

9.4	Drug-Drug Interactions	10
9.5	Drug-Food Interactions	11
9.6	Drug-Herb Interactions	11
9.7	Drug-Laboratory Test Interactions.....	11
10	CLINICAL PHARMACOLOGY	11
10.1	Mechanism of Action	11
10.2	Pharmacodynamics.....	11
10.3	Pharmacokinetics.....	12
11	STORAGE, STABILITY AND DISPOSAL.....	13
12	SPECIAL HANDLING INSTRUCTIONS.....	13
	PART II: SCIENTIFIC INFORMATION	14
13	PHARMACEUTICAL INFORMATION	14
14	CLINICAL TRIALS	14
14.1	Trial Design and Study Demographics	14
14.2	Study Results.....	16
14.3	Comparative Bioavailability Studies	19
15	MICROBIOLOGY	22
16	NON-CLINICAL TOXICOLOGY	22
	PATIENT MEDICATION INFORMATION	25

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

VYNDAMAX (tafamidis) is indicated for:

the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis (ATTR-CM), wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

1.1 Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (≥65 years of age): Safety and efficacy were demonstrated in this population.

2 CONTRAINDICATIONS

VYNDAMAX (tafamidis) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

VYNDAMAX (tafamidis) capsules and VYNDAQEL (tafamidis meglumine) capsules are different formulations with the active moiety tafamidis. To avoid dosing errors, it is important that prescriptions of tafamidis/tafamidis meglumine specify the salt form and the prescribed dose. VYNDAMAX and VYNDAQEL are not interchangeable on a per mg basis (see **10.3 Pharmacokinetics**, Section **14.3 Comparative Bioavailability Studies** and the Product Monograph for VYNDAQEL).

4.2 Recommended Dose and Dosage Adjustment

The recommended dose of VYNDAMAX (tafamidis) is 61 mg tafamidis (administered as one 61-mg tafamidis capsule) orally once daily.

The recommended dose of VYNDAQEL (tafamidis meglumine) is 80 mg administered as 4 x 20 mg tafamidis meglumine capsules (equivalent to 48.8 mg tafamidis) orally once daily.

The dose may be reduced to one capsule of 20 mg VYNDAQEL (tafamidis meglumine) (equivalent to 12.2 mg of tafamidis) if not tolerated (see **14 Clinical Trials** section and also Product Monograph for VYNDAQEL).

Special populations

Pregnant Women

VYNDAMAX should not be used during pregnancy (see **7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women**).

Women of childbearing potential should use appropriate contraception when taking VYNDAMAX and continue to use contraception for one month after stopping treatment.

Pediatrics (<18 years of age)

VYNDAMAX is not indicated in the pediatric population.

Geriatrics (≥65 years of age)

No dosage adjustment is required for elderly patients (≥65 years). Of the total number of patients receiving tafamidis meglumine in the ATTR-CM clinical study (n=441), 90.5% were 65 and over, with a median age of 75 years.

Renal or hepatic impairment

VYNDAMAX has not been studied in patients with severe hepatic impairment and use is not recommended in these patients. No dosage adjustment is required for patients with mild or moderate hepatic impairment. Data are limited in patients with severe renal impairment. No dosage adjustment is required for patients with renal impairment.

4.4 Administration

The capsule(s) should be swallowed whole and not crushed or cut. VYNDAMAX may be taken with or without food.

4.5 Missed Dose

If a dose is missed, the patient should take the dose as soon as remembered. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.

5 OVERDOSAGE

There is minimal clinical experience with overdose. During clinical trials, two patients diagnosed with ATTR-CM accidentally ingested a single tafamidis meglumine dose of 160 mg without adverse events. The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480 mg as a single dose.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medical Ingredients
Oral	Capsule 61 mg: A soft gelatin capsule (filled with a white to pink suspension) contains 61 mg of micronized tafamidis	Ammonium hydroxide 28%, butylated hydroxytoluene, gelatin, glycerin, iron oxide (red), polyethylene glycol 400, polysorbate 20, povidone (K-value 90), polyvinyl acetate phthalate, propylene glycol, sorbitol, and titanium dioxide

VYNDAMAX (tafamidis) 61 mg: reddish brown, opaque, oblong (approximately 21 mm) capsule with “VYN 61” printed in white. Thirty (30) capsules (one-month supply) supplied in a carton of 3 blister cards. Each blister card contains 10 capsules.

7 WARNINGS AND PRECAUTIONS

General

No studies have been conducted in organ transplant patients. The efficacy and safety of VYNDAMAX (tafamidis) in organ transplant patients have not been established. VYNDAMAX is not recommended in these patients.

Carcinogenesis and Mutagenesis

Carcinogenesis

There was no evidence of an increased incidence of neoplasia in the transgenic (Tg)-rasH2 mouse following repeated daily administration of tafamidis meglumine for 26 weeks at daily doses of 0, 10, 30 or 90 mg/kg. There was no evidence of increased incidence of neoplasia in a 2-year carcinogenicity study in rats at exposures 18-times the human Area Under Curve (AUC) at the clinical dose of 61 mg tafamidis (see **16 NON-CLINICAL TOXICOLOGY**).

Mutagenesis

There was no evidence of mutagenicity or clastogenicity *in vitro*, and an *in vivo* rat micronucleus study was negative.

Driving and Operating Machinery

VYNDAMAX has not been shown to influence the ability to drive and use machines.

Hepatic/Biliary/Pancreatic

VYNDAMAX has not been studied in patients with severe hepatic impairment and use is not recommended in these patients.

Renal

Limited data are available in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min).

Reproductive Health: Female and Male Potential

- **Teratogenic Risk**

Studies in animals have shown developmental toxicity. The potential risk for humans is unknown. VYNDAMAX should not be used during pregnancy (see **16 NON-CLINICAL TOXICOLOGY**).

Women of childbearing potential should use appropriate contraception when taking VYNDAMAX and continue to use contraception for 1-month after stopping treatment.

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well-controlled clinical studies with the use of VYNDAMAX in pregnant women. Studies in animals have shown developmental toxicity. The potential risk for humans is unknown. VYNDAMAX should not be used during pregnancy.

7.1.2 Breast-feeding

There are no clinical data available to support the presence of tafamidis in human breast milk. Nonclinical data demonstrate that tafamidis is secreted in the milk of lactating rats (see **16 NON-CLINICAL TOXICOLOGY**). When a drug is present in animal milk, it is likely the drug will be present in human milk. The effect of VYNDAMAX on nursing infants after administration to the mother has not been studied. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breast-fed infant, VYNDAMAX should not be used by nursing women.

7.1.3 Pediatrics

Pediatrics (<18 years of age): VYNDAMAX is not indicated and should not be prescribed in the pediatric population.

7.1.4 Geriatrics

Geriatrics (≥65 years of age): Safety and efficacy were demonstrated in this population.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

In clinical trials, the most frequently reported Treatment Emergent Serious Adverse Events (TESAEs) in the tafamidis meglumine 80 mg, tafamidis meglumine 20 mg and placebo groups respectively were condition aggravated (22.7%, 23.9% and 32.8%); cardiac failure (19.3%, 18.2%, and 22.6%), cardiac failure congestive (11.9%, 15.9% and 17.5%), cardiac failure acute (13.1%, 4.5% and 9.6%), fall (5.1%, 5.7% and 2.8%) and syncope (3.4%, 0%, 5.6%).

Treatment Emergent Adverse Events (TEAEs) with a higher incidence in the tafamidis meglumine 80 mg and 20 mg treatment group than placebo (≥2x placebo and reported by ≥4 patients) respectively, included cystitis (3.4%, 2.3% and 0%), sinusitis (5.7%, 5.7% and 0.6%), asthenia (10.2%, 12.5% and 6.2%), balance disorder (8.5%, 2.3% and 1.1%) and cataract (5.1%, 3.4% and 1.1%).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

The data across clinical trials reflect exposure of 377 ATTR-CM patients to either 20 mg or 80 mg (administered as four 20 mg capsules) of tafamidis meglumine (VYNDAQEL) daily for an average of 24.5 months (ranging from 1 day to 111 months). Tafamidis 61 mg (VYNDAMAX) was not administered

in the pivotal study. The population included adult patients diagnosed with ATTR-CM with baseline NYHA (New York Heart Association) Class I, Class II or Class III respectively at 9.1%, 61.4%, and 29.5% in the pooled tafamidis arm and at 7.3%, 57.1% and 35.6%, respectively on placebo. The mean age was approximately 75 years (ranging from 46 years to 91 years of age); >90% were male, and approximately 82% were Caucasian (see Study Results Table 6: Patient Demographics and Baseline Characteristics).

Adverse events were assessed from ATTR-CM clinical trials with tafamidis meglumine including a 30-month placebo-controlled trial in patients diagnosed with ATTR-CM. The frequency of adverse events in patients treated with tafamidis meglumine 20 mg (n=88) or 80 mg (n=176; administered as four 20 mg capsules) was comparable to placebo (n=177). Listed below are all causality adverse events reported in the pivotal clinical trial.

A similar proportion of tafamidis meglumine-treated patients compared to placebo discontinued due to an adverse event in the 30-month placebo-controlled trial in patients diagnosed with ATTR-CM [12 (6.8%), 5 (5.7%), and 11 (6.2%)] from the tafamidis meglumine 80 mg, tafamidis meglumine 20 mg, and placebo groups, respectively].

The most commonly reported TEAEs ($\geq 10\%$) in the tafamidis meglumine 80 mg and/or 20 mg groups that occurred at rates higher than placebo are as follows (Table 2).

Table 2 – Most common ($\geq 10\%$) Treatment-Emergent Adverse Events reported at a higher rate in the tafamidis meglumine 80 mg and/or 20 mg groups than in the placebo group (All Causality)

System Organ Class Preferred Term	Tafamidis 20 mg N=88 n (%)	Tafamidis 80 mg N=176 n (%)	Placebo N=177 n (%)
Cardiac disorders			
atrial fibrillation	16 (18.2%)	35 (19.9%)	33 (18.6%),
cardiac failure	30 (34.1%)	46 (26.1%)	60 (33.9%)
cardiac failure acute	4 (4.5%)	24 (13.6%)	17 (9.6%)
cardiac failure congestive	17 (19.3%)	22 (12.5%)	33 (18.6%)
General disorders and administration site conditions			
asthenia	11 (12.5)	18 (10.2)	11 (6.2)
edema peripheral	17 (19.3)	30 (17.0)	31 (17.5)
Infections and infestations			
bronchitis	9 (10.2)	21 (11.9)	19 (10.7)
pneumonia	10 (11.4)	23 (13.1)	17 (9.6)
Injury, poisoning and procedural complications			
fall	27 (30.7)	43 (24.4)	41 (23.2)
Musculoskeletal and connective tissue disorders			

muscle spasms	10 (11.4)	15 (8.5)	14 (7.9)
pain in extremity	6 (6.8)	27 (15.3)	20 (11.3)
Psychiatric disorders			
insomnia	12 (13.6)	20 (11.4)	22 (12.4)
Renal and urinary disorders			
hematuria	10 (11.4)	10 (5.7)	17 (9.6)
Respiratory, thoracic and mediastinal disorders			
Cough	16 (18.2)	21 (11.9)	30 (16.9)
Vascular disorders			
hypotension	12 (13.6)	19 (10.8)	19 (10.7)

The reported incidence of hypothyroidism was 6.8%, 5.7% and 5.6% in patients in the tafamidis meglumine 80 mg, 20 mg and placebo groups, respectively.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

The incidence of thyroxine abnormality $<0.8 \times \text{LLN}$ was greater in the tafamidis meglumine 80 mg group (29.7%) than in the tafamidis meglumine 20 mg (12.3%) and placebo (4.5%) groups. No clinically meaningful shifts in free thyroxine or thyroid stimulating hormone values were observed, and no corresponding signal in thyroid dysfunction was observed in the analysis of TEAEs (see **8.2 Clinical Trial Adverse Reactions** for rates of hypothyroidism reported in clinical trials).

Low neutrophil count ($<0.8 \times \text{LLN}$) was more frequent with tafamidis meglumine treatment than with placebo (1.9% tafamidis meglumine 80 mg, 1.2% tafamidis meglumine 20 mg, 0.6% placebo).

Elevated liver function tests were more frequent in the tafamidis meglumine 80 mg group (3.4%) than in the tafamidis meglumine 20 mg (2.3%) and placebo (1.1%) groups.

8.5 Post-Market Adverse Reactions

The following treatment emergent adverse drug reactions were observed in patients treated with tafamidis 61 mg:

Gastrointestinal disorders: abdominal discomfort, abdominal pain, constipation, diarrhea

Skin and subcutaneous tissue disorders: pruritus, rash

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

In vitro studies:

Cytochrome P450 Enzymes: Tafamidis induces CYP2B6 and CYP3A4 and does not induce CYP1A2.

Tafamidis does not inhibit cytochrome P450 enzymes CYP1A2, CYP3A4, CYP3A5, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and moderately inhibits CYP2C8.

UDP glucuronosyltransferase (UGT): Tafamidis inhibits intestinal activities of UGT1A1 but neither induces nor inhibits other UDP glucuronosyltransferase (UGT) systemically.

Transporter Systems: Tafamidis inhibits breast cancer resistant protein (BCRP).

In vitro studies and model predictions show that tafamidis has a potential to inhibit the organic anion transporters OAT1 and OAT3 at clinically relevant concentrations.

Tafamidis did not show a potential to inhibit Multi-Drug Resistant Protein (MDR1) (also known as P-glycoprotein; P-gp), organic cation transporter OCT2, multidrug and toxin extrusion transporters MATE1 and MATE2K and, organic anion transporting polypeptide OATP1B1 and OATP1B3.

Clinical studies:

Transporter Systems: Tafamidis inhibits breast cancer resistant protein (BCRP). In a clinical study in healthy participants, the exposure of the BCRP substrate rosuvastatin increased approximately 2-fold following multiple doses of 61 mg tafamidis daily dosing.

In a clinical study (n=12) using healthy participants, the renal clearance of the OAT3 substrate rosuvastatin did not change following multiple doses of 61 mg tafamidis daily dosing. This suggests that any inhibition of OAT3 by tafamidis may not result in clinically significant interactions with OAT3 substrates.

9.4 Drug-Drug Interactions

The drugs listed in Table 3 are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction.

Table 3 - Established or Potential Drug-Drug Interactions

Drug Name	Source of Evidence	Effect	Clinical comment
CYP3A4 substrates (e.g., midazolam, triazolam)	<i>In vivo</i>	Tafamidis meglumine (20 mg) did not affect the PK of CYP3A4 substrate midazolam; the effect of 80 mg has not been studied.	<i>In vitro</i> , tafamidis meglumine induces CYP3A4 and may decrease exposure of substrates of this CYP enzyme at the higher dose of 80 mg. Caution should be exercised when VYNDAMAX (tafamidis) is co-administered with CYP3A4 substrates. Dose adjustment may be needed for these substrates.

Drug Name	Source of Evidence	Effect	Clinical comment
Substrates of breast cancer resistant protein BCRP (e.g., methotrexate, rosuvastatin, imatinib)	<i>In vitro, in vivo</i>	Tafamidis inhibits BCRP systemically and in the GI tract and may increase exposure of substrates of this transporter.	Caution should be exercised when VYNDAMAX is co-administered with BCRP substrates. Dose adjustment may be needed for these substrates.
Substrates of organic anion transporters 1 (OAT1) and OAT3 (e.g., antiretroviral agents, diuretics, methotrexate, NSAIDs, olmesartan, pravastatin)	<i>In vitro, in vivo</i>	In vitro data indicate that tafamidis has a potential to inhibit OAT1 and may therefore decrease exposure of substrates of this transporter.	Caution should be exercised when VYNDAMAX is co-administered with OAT1 and OAT3 substrates. Dose adjustment may be needed for these substrates. There is limited clinical evidence to suggest that any inhibition of OAT3 (specifically) by tafamidis may not result in clinically significant interactions with OAT3 substrates.

9.5 Drug-Food Interactions

Concomitant administration of VYNDAMAX with a high fat, high calorie meal increased the C_{max} by 32%, but did not affect the AUC. VYNDAMAX is to be administered with or without food.

9.6 Drug-Herb Interactions

No interaction studies have been performed evaluating the effect of herbal products on tafamidis.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Tafamidis is a selective stabilizer of transthyretin (TTR). Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.

10.2 Pharmacodynamics

A TTR stabilization assay was utilized as a pharmacodynamic marker and assessed the stability of the TTR tetramer under denaturation conditions. Tafamidis stabilized both the wild-type TTR tetramer and the tetramers of 14 TTR variants tested clinically after once-daily dosing. Tafamidis also stabilized the TTR tetramer for an additional 25 variants tested *ex vivo*.

The 80 mg dose for VYNDAQEL (tafamidis meglumine) was selected based on maximal TTR % stabilization data from PK studies. The clinical relevance of a higher TTR stabilization is not known.

The recommended dose of VYNDAMAX (tafamidis) is 61 mg orally once daily.

Cardiac Electrophysiology

At single dose of 400 mg, approximately 2.2 times the steady state peak plasma concentration (C_{max}) at the recommended dose, tafamidis does not prolong the QTc interval to any clinically relevant extent.

10.3 Pharmacokinetics

Table 4 - Summary of Tafamidis Pharmacokinetic Parameters¹ in Healthy Volunteers after a Single Dose of 1 x 61 mg Tafamidis Capsule.

Condition N, n ²	AUC _{0-168hr} (mcg.hr/mL)	AUC _i (mcg.hr/mL)	C _{max} (mcg/mL)	T _{max} (hr)	t _{1/2} (hr)
Fasting 16, 15	210.1 (14)	225.9 (12)	3.886 (19)	4.00 (2.00 – 12.00)	48.60 (24)
Fed 17, 14	236.7 (20)	247.9 (18)	5.125 (16)	3.00 (0.50 – 6.03)	49.81 (26)

1. Arithmetic mean (%CV) for all except: median (range) for T_{max}

2. N = Number of subjects in the treatment group; n = Number of Subjects where t_{1/2} and AUC_i were determined.

Absorption:

After oral administration of VYNDAMAX (tafamidis) once daily, the maximum peak concentration (C_{max}) is achieved at a median time (t_{max}) within 4 hours after dosing in the fasted state.

Concomitant administration of VYNDAQEL (tafamidis meglumine) with a high fat, high calorie meal decreased the C_{max} by 15%, but did not affect the AUC. Concomitant administration of VYNDAMAX (tafamidis) with a high fat, high calorie meal increased the C_{max} by 32%, but did not affect the AUC. VYNDAQEL and VYNDAMAX are to be administered with or without food.

VYNDAMAX and VYNDAQEL are not interchangeable on a per mg basis. (See **4.1 Dosing Considerations** and **4.2 Recommended Dose and Dosage Adjustment**)

Distribution:

Tafamidis is highly protein bound (>99%) in plasma. The apparent steady-state volume of distribution is 18.5 liters in a 75 kg adult.

Metabolism:

While there is no explicit evidence of biliary excretion of tafamidis in humans, based on preclinical data, it is suggested that tafamidis is metabolized by glucuronidation and excreted via the bile. This route of metabolism and excretion is likely in humans, as approximately 59% of the total administered dose is recovered in feces mostly as unchanged drug, and approximately 22% recovered in urine mostly as the glucuronide metabolite.

Elimination:

The mean half-life of tafamidis is approximately 49 hours. The apparent oral clearance of tafamidis is 0.263 L/hr. The degree of drug accumulation at steady state after repeated tafamidis daily dosing is approximately 2.5-fold greater than that observed after a single dose.

Special Populations and Conditions

Ethnic origin: No clinically significant differences in the pharmacokinetics of tafamidis were observed based on race/ethnicity (Caucasian and Japanese).

Pediatrics: Tafamidis has not been studied and is not indicated in this population.

Hepatic Insufficiency: Pharmacokinetic data indicated decreased systemic exposure (approximately 40%) and approximately 68% increase of total clearance (0.52 L/h versus 0.31 L/h) of tafamidis meglumine in subjects with moderate hepatic impairment (Child-Pugh Class B) compared to healthy subjects. As TTR levels are lower in patients with moderate hepatic impairment than in healthy subjects, the exposure of tafamidis relative to the amount of TTR would be sufficient for stabilization of the TTR tetramer in these patients.

Exposure to VYNDAMAX was similar between subjects with mild hepatic impairment (Child-Pugh Class A) and healthy subjects.

The pharmacokinetics of VYNDAMAX in patients with severe hepatic impairment (Child-Pugh Class C) is unknown.

Renal Insufficiency: VYNDAMAX has not specifically been evaluated in patients with renal impairment. Limited data are available in patients with severe renal impairment ($\text{CrCl} \leq 30$ mL/min).

11 STORAGE, STABILITY AND DISPOSAL

Store VYNDAMAX at room temperature 15°C to 25°C.

12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions for this drug product.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: tafamidis

Chemical name: 2 (3,5 dichlorophenyl) 1,3 benzoxazole 6 carboxylic acid

Molecular formula and molecular mass: $C_{14}H_7Cl_2NO_3$, and the molecular mass is 308.12 g/mol

Structural formula:



Physicochemical properties: Tafamidis is a white to pink powder. It is practically insoluble or insoluble in water and very slightly soluble in methanol.

Aqueous Solubility of Tafamidis

Aqueous Solution	pH	Solubility (mg tafamidis/mL)
Water	7.6	0.0175
0.02M Acetate-phosphate buffer	2.6	< 0.002
0.02M Acetate-phosphate buffer	5.3	< 0.002
0.02M Acetate-phosphate buffer	6.3	0.002
0.02M Acetate-phosphate buffer	7.0	0.0158
0.02M Acetate-phosphate buffer	7.8	0.0728
0.02M Acetate-phosphate buffer	8.0	0.140

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

The pivotal study was conducted with VYNDAMAX (tafamidis meglumine). Tafamidis 61 mg (VYNDAMAX) was not administered in the pivotal study.

Table 5 - Summary of the Pivotal Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)
---------	--------------	--	--------------------

B3461028	Double-blind, placebo-controlled, randomized	Tafamidis meglumine 20 mg or 80 mg, or placebo, oral, once daily for 30 months	441 patients enrolled into the study n=177 in the placebo arm n=88 in the tafamidis meglumine 20 mg arm n=176 in the tafamidis meglumine 80 mg arm.
----------	--	--	--

Efficacy of tafamidis meglumine was demonstrated in a multicenter, international, double-blind, placebo-controlled, randomized study in 441 patients with wild type or hereditary ATTR-CM.

Eligible patients had ATTR-CM confirmed by biopsy specimens obtained from cardiac and noncardiac sites and, in patients without ATTRm, by the presence of transthyretin precursor protein confirmed on immunohistochemical analysis, scintigraphy, or mass spectrometry.

Patients were randomized to either tafamidis meglumine (VYNDAQEL) 20 mg (n=88) or 80 mg [administered as four 20 mg tafamidis meglumine capsules] (n=176) or matching placebo (n=177) once daily, in addition to standard of care (e.g., diuretics) for 30 months. Treatment assignment was stratified by the presence or absence of a variant TTR genotype and by baseline NYHA Class. Transplant patients were excluded from this study.

Table 6: Patient Demographics and Baseline Characteristics

Characteristic	Pooled Tafamidis meglumine N=264	Placebo N=177
Age — year		
Mean (Standard Deviation)	74.5 (7.2)	74.1 (6.7)
Median (minimum, maximum)	75 (46, 88)	74 (51, 89)
Sex — number (%)		
Male	241 (91.3)	157 (88.7)
Female	23 (8.7)	20 (11.3)
TTR Genotype — number (%)		
ATTRm	63 (23.9)	43 (24.3)
ATTRwt	201 (76.1)	134 (75.7)
NYHA Class — number (%)		
NYHA Class I	24 (9.1)	13 (7.3)
NYHA Class II	162 (61.4)	101 (57.1)
NYHA Class III	78 (29.5)	63 (35.6)

Abbreviations: ATTRm = variant transthyretin amyloid, ATTRwt = wild type transthyretin amyloid, NYHA=New York Heart Association.

14.2 Study Results

The primary analysis used a hierarchical combination applying the method of Finkelstein-Schoenfeld (F-S) to all-cause mortality and frequency of cardiovascular-related hospitalizations, which was defined as the number of times a subject is hospitalized for cardiovascular-related morbidity. The method compared each patient to every other patient within each stratum in a pair-wise manner that proceeded in a hierarchical fashion using all-cause mortality followed by frequency of cardiovascular-related hospitalizations when patients cannot be differentiated based on mortality.

This analysis demonstrated a significant reduction ($p=0.0006$) in all-cause mortality and frequency of cardiovascular-related hospitalizations in the pooled tafamidis meglumine 20 mg and 80 mg groups versus placebo (Table 7).

Table 7: Primary Analysis Using Finkelstein-Schoenfeld (F-S) Method of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations

Primary Analysis	Pooled Tafamidis meglumine N=264	Placebo N=177
Number (%) of Subjects Alive* at Month 30	186 (70.5)	101 (57.1)
Average Cardiovascular-related Hospitalizations During 30 months (per patient per year) Among Those Alive at Month 30	0.297	0.455
p-value from F-S Method	0.0006	

* Heart transplantation and cardiac mechanical assist devices implantation are considered indicators of approaching end stage. As such, these subjects are treated in the analysis as equivalent to death. Therefore, such subjects are not included in the count of "Number of Subjects Alive at Month 30" even if such subjects are alive based on 30-month vital status follow-up assessment.

The hazard ratio from the all-cause mortality Cox-proportional hazard model for pooled tafamidis meglumine versus placebo was 0.70 (95% confidence interval [CI] 0.51, 0.96), indicating a 30% relative reduction in the risk of death relative to the placebo group ($p=0.026$).


The difference in mortality events between groups was attributable to CV related events.

Overall, 20.8% of the pooled tafamidis meglumine and 33.3% of the placebo groups had CV-related deaths.

Non-CV-related deaths were reported in 5.3% of the pooled tafamidis meglumine and 7.3% of the placebo group.

A Kaplan-Meier plot of time to event all-cause mortality is presented in Figure 1.

Figure 1: All-Cause Mortality*



Subjects Remaining at Risk (Cumulative events)												
Pooled Tafamidis meglumine	264	259	252	244	235	222	216	209	200	193	99	0
	0	5	12	20	29	42	48	55	64	71	78	78
Placebo	177	173	171	163	161	150	141	131	118	113	51	0
	0	4	6	14	16	27	36	46	59	64	75	76

*Heart

transplants and cardiac mechanical assist devices treated as death. Hazard ratio from Cox proportional hazards model with treatment, TTR genotype (variant and wild type), and NYHA baseline classification (NYHA Classes I and II combined and NYHA Class III) as factors.

There were significantly fewer cardiovascular-related hospitalizations with tafamidis meglumine compared with placebo with a reduction in risk of 32% (Table 8).

Table 8: Cardiovascular-Related Hospitalization Frequency

	Pooled Tafamidis meglumine N=264	Placebo N=177
Total (%) Number of Subjects with Cardiovascular-related Hospitalizations	138 (52.3)	107 (60.5)
Cardiovascular-related Hospitalizations per Year*	0.48	0.70
Pooled Tafamidis vs Placebo Treatment Difference (Relative Risk Ratio)*	0.68	
p-value*	<0.0001	

*This analysis was based on a Poisson regression model with treatment, TTR genotype (variant and wild type), New York Heart Association (NYHA) Baseline classification (NYHA Classes I and II combined and NYHA Class III), treatment-by-TTR genotype interaction, and treatment-by-NYHA baseline classification interaction terms as factors.

The treatment effect of tafamidis meglumine on functional capacity and health status was assessed by the 6-Minute Walk Test (6MWT) and the Kansas City Cardiomyopathy Questionnaire-Overall Summary

(KCCQ-OS) score, respectively. A significant treatment effect favoring tafamidis meglumine was first observed at Month 6 and remained significant through Month 30 for both the 6MWT and the KCCQ-OS.

The Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score is composed of four domains including Total Symptoms (Symptom Frequency and Symptom Burden), Physical Limitation, Quality of Life, and Social Limitation. The Overall Summary score and domain scores range from 0 to 100, with higher scores representing better health status. The distribution for change from Baseline to Month 30 for KCCQ-OS shows that the proportion of patients with worse KCCQ-OS scores was lower for the pooled tafamidis meglumine-treated group compared to placebo, and the proportion with improved scores was higher.

Results of the primary analysis, the components of the primary analysis, functional capacity (6MWT) and health status (KCCQ-OS) at Month 30, cardiovascular-related mortality, and TTR-stabilization at Month 1 were analyzed by individual doses (80 mg and 20 mg) compared to placebo.

In the pivotal trial, comparable TTR stabilization rates were seen for both the 20 mg and 80 mg doses at 12 months (83% and 88%, respectively).

Both tafamidis meglumine doses (80 mg and 20 mg) appeared to be as effective. However, the study was not powered to distinguish between doses. The hazard ratios from the all-cause mortality for the 80 mg and 20 mg tafamidis meglumine doses relative to placebo were 0.69 (95% CI 0.49, 0.98) and 0.72 (95% CI 0.45, 1.14), respectively. The relative risk ratios for CV-related hospitalization between the tafamidis meglumine 80 mg and 20 mg relative to placebo were 0.70 (95% CI 0.57, 0.86) and 0.66 (95% CI 0.51, 0.86).

The key secondary endpoints (6MWT and the KCCQ-OS score) were also comparable between doses.


Potential benefit for the 80 mg dose was suggested in post hoc exploratory analyses of reduction of cardiac biomarker NT-proBNP at month 30 and reaching a difference from placebo at an earlier time point.

Results from F-S method represented by the win ratio for the combined endpoint and its components (all-cause mortality and frequency of CV-related hospitalization) favored tafamidis meglumine versus placebo across wild type, variant and NYHA Class I & II subgroups.

In NYHA Class III subgroup, the proportion of patients with CV-related hospitalizations were 76.9% vs 58.7% and CV mortality were 51.3% vs 49.2% for pooled tafamidis meglumine and placebo treatment groups, respectively.

Analyses of 6MWT and KCCQ-OS favored tafamidis meglumine relative to placebo within each subgroup.

Figure 2: Results by Subgroup, Dose, and Components of Primary Analysis



Abbreviations: ATTRm = variant transthyretin amyloid, ATTRwt = wild type transthyretin amyloid, F-S = Finkelstein Schoenfeld, CI = Confidence Interval

*F-S results presented using win ratio (based on all-cause mortality and frequency of cardiovascular hospitalization) Win ratio is the number of pairs of treated-patient “wins” divided by number of pairs of placebo patient “wins”. Heart transplants and cardiac mechanical assist devices treated as death.

There are no clinical data in patients of NYHA Class IV at baseline.

14.3 Comparative Bioavailability Studies

Single Dose Study

The relative bioavailability of VYNDAMAX (tafamidis) capsules was compared to that of VYNDAQEL (tafamidis meglumine) capsules in a single dose 4-way crossover comparative bioavailability study in 18 healthy adult male subjects. Single doses were administered as 1 x 61 mg tafamidis capsules (VYNDAMAX) or 48.8 mg tafamidis [4 x 20 mg tafamidis meglumine capsules (VYNDAQEL)] under both fasting and high fat/high calorie fed conditions. The results in the tables below demonstrate a comparable bioavailability under both fasting and fed conditions.

Table 9 - SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Single Dose under Fasting Conditions

Tafamidis (1 x 61 mg tafamidis vs 48.8 mg tafamidis administered as 4 x 20 mg tafamidis meglumine) From measured data Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹ N=16	Reference ² N=16	% Ratio of Geometric Means	90% Confidence Interval
AUC ₀₋₇₂ (mcg.h/mL)	150.5 148.6 (12)	144.8 146.2 (17)	103.9	98.8 - 109.4
AUC _{0-168 hr} (mcg.h/mL)	216.1 210.1 (14)	195.1 198.6 (25)	110.8	104.2 - 117.7
AUC _I ^{3,4} (mcg.h/mL)	233.7 225.9 (12)	203.4 198.4 (17)	114.9	106.7 - 123.7
C _{max} (mcg/mL)	3.857 3.886 (19)	4.835 4.881 (19)	79.8	72.8 - 87.4
T _{max} ⁵ (h)	4.00 (2.00-12.0)	1.50 (0.500-4.05)		
T _½ ^{3,4,6} (h)	48.60 (24)	42.62 (24)		

¹ VYNDAMAX (tafamidis) 61 mg capsule

² VYNDAQEL (tafamidis meglumine) 20 mg capsule (equivalent to 12.2 mg of tafamidis)

³ n = 15, Test

⁴ n = 14, Reference

⁵ Expressed as median (range) only

⁶ Expressed as the arithmetic mean (CV%) only

Table 10 - SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Single Dose under Fed Conditions

Tafamidis (1 x 61 mg tafamidis vs 48.8 mg tafamidis administered as 4 x 20 mg tafamidis meglumine) From measured data				
Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹ N=17	Reference ² N=16	% Ratio of Geometric Means	90% Confidence Interval
AUC ₀₋₇₂ (mcg.h/mL)	164.8 165.1 (11)	137.3 136.1 (14)	120.1	114.1 - 126.3
AUC _{0-168 hr} (mcg.h/mL)	233.6 236.7 (20)	193.3 189.4 (18)	120.8	113.7 - 128.4
AUC _t ^{3,4} (mcg.h/mL)	247.9 247.9 (18)	208.1 208.1 (22)	119.2	110.5 - 128.5
C _{max} (mcg/mL)	5.106 5.125 (16)	4.132 4.153 (14)	123.6	112.9 - 135.2
T _{max} ⁵ (h)	3.00 (0.500-6.03)	3.00 (1.00-6.00)		
T _½ ^{3,4,6} (h)	49.81 (26)	47.11 (23)		

¹ VYNDAMAX (tafamidis) 61 mg capsule

² VYNDAQEL (tafamidis meglumine) 20 mg capsule (equivalent to 12.2 mg of tafamidis)

³ n = 14, Test

⁴ n = 15, Reference

⁵ Expressed as median (range) only

⁶ Expressed as the arithmetic mean (CV%) only

Multiple Dose Study

The relative bioavailability of VYNDAMAX (tafamidis) capsules was compared to that of VYNDAQEL (tafamidis meglumine) capsules in a multiple dose 2-way crossover comparative bioavailability study in 30 healthy adult male subjects. Subjects were dosed for 7 days; receiving 61 mg tafamidis [administered as 1 x 61 mg tafamidis capsules (VYNDAMAX)] or 48.8 mg tafamidis [administered as 4 x 20 mg tafamidis meglumine capsules (VYNDAQEL)] twice daily on Days 1 and 2, followed by once daily for Days 3 - 7 under fasting conditions. The results from Day 7 sampling in the table below demonstrate that there was not a significant difference in the rate and extent of absorption of tafamidis from the two formulations.

Table 11 - SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA**Multiple Dose under Fasting Conditions**

Tafamidis (1 x 61 mg tafamidis vs 48.8 mg tafamidis administered as 4 x 20 mg tafamidis meglumine) From measured data Adjusted Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval
AUC _{tau} ³ (mcg.h/mL)	170.0 174.4 (24)	166.2 169.6 (21)	102.3	98.0 - 106.8
C _{max} (mcg/mL)	8.553 8.778 (24)	9.087 9.241 (19)	94.1	89.1 - 99.4
C _{min} (mcg/mL)	5.336 5.524 (28)	4.900 5.060 (27)	108.9	103.7 - 114.3
T _{max} ⁴ (h)	4.00 (2.00 – 8.00)	2.00 (0.50, 6.02)		

¹ VYNDAMAX (tafamidis) 61 mg capsule² VYNDAQEL (tafamidis meglumine) 20 mg capsule (equivalent to 12.2 mg of tafamidis)³ AUC_{tau} = area under curve from time 0 to time tau, the dosing interval, where tau = 24 hours for daily dosing⁴ Expressed as median (range)**15 MICROBIOLOGY**

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

The non-clinical program of tafamidis meglumine was based on conventional studies of safety pharmacology, pharmacodynamic and pharmacokinetic studies, repeat-dose toxicity, reproductive and developmental toxicity, carcinogenicity, genetic toxicity, phototoxicity, and immunotoxicity. Non-clinical toxicology findings which are relevant for the safe use of the drug and/or contribute to the understanding of a drug's toxicological profile are summarized below.

General Toxicology and Carcinogenicity

In repeat-dose toxicity and carcinogenicity studies, even though there was no evidence of neoplasia, the liver and/or kidney appeared as target organs for toxicity in the different species tested. Liver effects were observed at exposures approximately ≥0.7-times the human exposure at a dose of 61 mg tafamidis.

Significant non-neoplastic lesions were noted in the kidneys (nephrosis) and liver (centrilobular hypertrophy and single cell necrosis) in the Tg-rasH2 mice at dose levels ≥ 2.8-times the clinical dose of 61 mg tafamidis. Renal nephrosis was noted only in male (Tg)-rasH2 mice with a higher incidence and

severity at 90 mg/kg/day and not observed at ≤ 30 mg/kg/day, with corresponding AUC₂₄ values ≤ 2.8 -times the human steady state AUC₂₄ at the clinical dose of 61 mg tafamidis.

Reproductive and Developmental Toxicity

Fertility

There were no effects of tafamidis meglumine on fertility, reproductive performance, or mating behavior in the rat at any dose up to 30 mg/kg (human equivalent dose of tafamidis meglumine greater than 4.8 mg/kg/day). Rats were dosed daily (5, 15, and 30 mg/kg/day) prior to cohabitation (for at least 15 days for females and 28 days for males), throughout the cohabitation period to the day prior to termination of males and through to implantation of females (Gestation Day 7). No adverse effects were noted on male rats at any dose. Females had statistically significant weight loss and decreased feed consumption in the highest dose group during the first week of dosing.

The paternal and maternal no observed effect level for reproductive toxicity of tafamidis meglumine is 30 mg/kg/day, 5.5-times the clinical dose of 61 mg tafamidis.

Placental and milk transfer

Pregnant and lactating female rats were administered repeated daily oral doses of tafamidis meglumine (15 mg/kg/day) followed by a single oral gavage dose of ¹⁴C-tafamidis meglumine on Lactation Day 4 or 12. Radiolabelled material was observed in blood and fetal tissues and distribution was widespread by the first timepoint analyzed, suggesting that dose-related material had crossed the placental barrier. The concentrations in fetal tissue were generally higher on Day 19 of gestation as compared to Day 15 of gestation. Radioactivity was observed in milk by 1-hour post-dose and increased thereafter. The ratio of the highest radioactivity associated with ¹⁴C-tafamidis meglumine in milk (8 hours post-dose) vs. plasma (1-hour post-dose) was approximately 1.6 on Day 12, indicating tafamidis meglumine is transferred to milk after oral administration.

Developmental toxicity

In an embryo-fetal developmental toxicity study in rabbits, oral administration of tafamidis meglumine (0, 0.5, 2, and 8 mg/kg/day) throughout organogenesis resulted in increased embryofetal mortality, reduced fetal body weights, and an increased incidence of fetal malformations at 8 mg/kg/day (approximately 9.1 times the human exposure of 61 mg tafamidis based on AUC), which was also maternally toxic. Increased incidences of fetal skeletal variations were observed at doses ≥ 0.5 mg/kg/day (approximately equivalent to the human exposure of 61 mg tafamidis based on AUC).

In an embryo-fetal development toxicity study in rats, oral administration of tafamidis (15, 30, and 45 mg/kg/day) from Gestation Day 7 through 17 resulted in decreased fetal weights at ³ 30 mg/kg/day (approximately ³ 9.5-times the human AUC at the clinical dose of 61 mg tafamidis). The no observable adverse effect level (NOAEL) for embryo-fetal development in rats was 15 mg/kg/day (6.4 times the human exposure of 61 mg tafamidis based on AUC).

In the rat pre- and postnatal development study with tafamidis, pregnant rats were orally administered tafamidis meglumine at doses of 5, 15, or 30 mg/kg/day from Gestation Day 7 through Lactation Day 20. High pup mortality at 30 mg/kg/day resulted in early termination of this group. Decreased pup survival and reduced pup weights were also noted at 15 mg/kg/day. Decreased pup weights in males were associated with delayed sexual maturation (preputial separation) at 15 mg/kg/day. Impaired performance in a water-maze test for learning and memory was observed at 15 mg/kg/day. The NOAEL for viability and growth in the F1 generation offspring following maternal dose administration during

pregnancy and lactation with tafamidis was 5 mg/kg/day (human equivalent dose of tafamidis=0.8 mg/kg/day), a dose approximately equivalent to the clinical dose of 61 mg tafamidis.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

VYNDAMAX™

Tafamidis capsules

Read this carefully before you start taking **VYNDAMAX** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **VYNDAMAX**.

What is VYNDAMAX used for?

VYNDAMAX is used to treat adults with cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Cardiomyopathy is a disease of the heart muscle that makes it harder for your heart to pump blood to the rest of your body. VYNDAMAX reduces death and hospitalization related to heart problems.

VYNDAMAX is not for use in patients less than 18 years of age.

How does VYNDAMAX work?

VYNDAMAX is used to treat a disease called transthyretin amyloid cardiomyopathy (also known as ATTR-CM). In ATTR-CM, a protein called transthyretin (TTR) breaks up and may form fibrils called amyloid. Amyloid can build up between cells in your heart preventing your heart from working normally. This can cause heart-related symptoms and problems. VYNDAMAX is used to prevent the TTR protein from breaking up and slows the deposit of amyloid fibrils in the heart.

What are the ingredients in VYNDAMAX?

Medicinal ingredients: tafamidis

Non-medicinal ingredients: ammonium hydroxide 28%, butylated hydroxytoluene, gelatin, glycerin, iron oxide (red), polyethylene glycol 400, polysorbate 20, povidone (K value 90), polyvinyl acetate phthalate, propylene glycol, sorbitol, and titanium dioxide

VYNDAMAX comes in the following dosage forms:

Capsules: 61 mg

Do not use VYNDAMAX if:

- You are allergic to tafamidis or any of the ingredients in this medicine, including non-medicinal ingredients, or component of the container.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take [VYNDAMAX]. Talk about any health conditions or problems you may have, including if you:

- have liver problems
- have severe kidney problems
- had an organ transplant

- are pregnant or plan to become pregnant. VYNDAMAX may harm your unborn baby. Tell your healthcare professional right away if you become pregnant or think you may be pregnant during treatment with VYNDAMAX. If you are a woman of childbearing potential, you should use appropriate contraception during treatment with VYNDAMAX. You should also continue to use appropriate contraception for one month after stopping treatment.
- are breast-feeding or plan to breast-feed. It is not known if VYNDAMAX passes into breast milk. You should not breast-feed during treatment with VYNDAMAX. Talk to your healthcare professional about the best way to feed your baby during treatment with VYNDAMAX.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with VYNDAMAX:

- midazolam and triazolam, sedative drugs
- methotrexate and imatinib, drugs used to treat cancer
- rosuvastatin and pravastatin, drugs used to lower cholesterol
- olmesartan, used to treat high blood pressure
- acetylsalicylic acid, ibuprofen, naproxen, and other non-steroidal anti-inflammatory drugs
- drugs used to treat HIV/AIDS
- diuretics or water pills, used to treat high blood pressure

How to take VYNDAMAX:

- Take VYNDAMAX exactly as your healthcare professional tells you to.
- VYNDAMAX capsules should be swallowed whole and not crushed or cut open.

Usual dose:

- Take one (1) VYNDAMAX 61 mg capsule once a day, with or without food.
- Your healthcare professional may reduce your dose to one capsule of 20 mg VYNDAQEL (tafamidis meglumine) if you can't tolerate the usual VYNDAMAX dose (for information on tafamidis meglumine 20 mg, See Product Monograph for VYNDAQEL, **PATIENT MEDICATION INFORMATION**).

Overdose:

If you think you, or a person you are caring for, have taken too much VYNDAMAX, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next dose at your regularly scheduled time. Do not take 2 doses at the same time.

What are possible side effects from using VYNDAMAX?

These are not all the possible side effects you may have when taking VYNDAMAX. If you experience any side effects not listed here, tell your healthcare professional.

- fall
- sinusitis (congested nose)
- asthenia (feeling weak or a lack of energy)
- feeling unbalanced when standing or walking
- cataract (clouding of the lens in your eye)
- Abdominal discomfort (unpleasant sensation in the stomach)
- Abdominal pain (stomachache)
- Constipation
- Diarrhea
- Pruritis: itching or itchy skin
- Rash

VYNDAMAX may cause abnormal blood test results. Your healthcare professional will decide when to perform blood tests and will interpret the results.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
Cystitis (bladder infection): increased need to urinate, pain in the pelvis or lower back, frequent urination during the night, cloudy urine that may contain blood, burning sensation when passing urine.		X	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store at room temperature (15 to 25°C).
- Keep out of reach and sight of children.

If you want more information about VYNDAMAX:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.pfizer.ca, or by calling 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC.

Last Revised AUG 16, 2022